2025-06-10-Jefferies-Mineralys_Therapeutics（MLYS）_新型降压药；市场共识已预期大规模推出-首次覆盖_持有_49页_12mb

MLYS Summary

Key Points

• Product: Lorundrostat, a novel aldosterone synthase inhibitor (ASI) for hypertension, with positive Phase III data.
• Approval: File for FDA approval in 2026, with launch likely by 2027.
• Efficacy: Demonstrated 12-week SBP reduction of 9.1-11.7 mmHg placebo-adjusted, comparable to competitor AZN's baxdrostat.
• Safety: Hyperkalemia rates (K >6.0 mmol/L) are low (~2%) managed by healthcare providers.
• Competition: Headquartered by AZN's baxdrostat (commercially stronger due to manufacturing/distribution). Other late-stage ASIs (Boehringer Ingelheim, Corxel, Roche) under development.
• Market Opportunity: Targeting $1-2B peak sales for hypertension alone, plus potential expansion to CKD and OSA.
• Valuation: Jefferies (Hold) rating with $15 PT; $1B market cap assumes $1B peak sales revenue discounted at 12%.
• Risks: Payer access barriers, hyperkalemia management costs, competition/steep price declines impacting revenue consensus.
• M&A: Potential partnership to reduce SG&A burden, actively exploring US commercialization partners.

Catalysts

• AZN's Phase III hypertension data in H2 2025.
• MLYS Phase II CKD & OSA topline data in Q2 2025 (CKD) & YE 2025/early 2026 (OSA).

Strategic Considerations

• Positioned for strategic partnerships to accelerate commercialization.
• Opportunity exists for M&A given high synergistic potential with large pharma with presence in cardiovascular therapeutics.